Owkin
Owkin is an AI biotech company focused on decoding complex biology to find the right treatment for every patient. Their core technology, Owkin K, is an agentic AI platform that integrates multimodal patient data with AI agents to accelerate drug discovery, development, and diagnostics. The company operates through specialized entities like Epkin (drug development), Owkin Dx (AI diagnostics), and Bioptimus (biology foundation model). Owkin leverages cutting-edge AI, including reinforcement learning, LLMs, and multimodal foundation models, with a strong emphasis on data access from a network of academic partners. They have strategic deals with Sanofi and BMS and are recognized for their contributions to AI in life sciences.
Owkin
Owkin is an AI biotech company focused on decoding complex biology to find the right treatment for every patient. Their core technology, Owkin K, is an agentic AI platform that integrates multimodal patient data with AI agents to accelerate drug discovery, development, and diagnostics. The company operates through specialized entities like Epkin (drug development), Owkin Dx (AI diagnostics), and Bioptimus (biology foundation model). Owkin leverages cutting-edge AI, including reinforcement learning, LLMs, and multimodal foundation models, with a strong emphasis on data access from a network of academic partners. They have strategic deals with Sanofi and BMS and are recognized for their contributions to AI in life sciences.
TL;DR
Founded: 2016
Domain: Biotechnology research / AI-for-health
Core product: Owkin K agentic AI platform (multimodal, federated learning)
Notable investors: Sanofi (180M), GV, F-Prime, Bpifrance
Employee count (reported): 457
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Accelerating drug discovery, clinical development, biomarker discovery, and diagnostic development by analyzing multimodal patient and biological data while preserving data privacy.
Founded
2016
Industry
Biotechnology Research
Tech Stack
Funding Track Record
25,000,000
May 2020 extension reported as $25M, bringing that round's total to ~ $52–55M
180,000,000
Sanofi made a $180M equity investment and entered a strategic collaboration
Crunchbase and other records indicate a Series B closed in June 2022